Catalyst Biosciences, Inc. (CBIO)
| Market Cap | 10.95M |
| Revenue (ttm) | 3.23M |
| Net Income (ttm) | 11.88M |
| Shares Out | 37.76M |
| EPS (ttm) | 0.38 |
| PE Ratio | 0.73 |
| Forward PE | n/a |
| Dividend | $1.43 (493.10%) |
| Ex-Dividend Date | Sep 21, 2022 |
| Volume | 949,083 |
| Open | 0.308 |
| Previous Close | 0.292 |
| Day's Range | 0.272 - 0.310 |
| 52-Week Range | 0.092 - 0.650 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 16.32 (+5,527.59%) |
| Earnings Date | Mar 29, 2023 |
About CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The compan... [Read more]
Financial Performance
In 2021, CBIO's revenue was $7.34 million, a decrease of -64.97% compared to the previous year's $20.95 million. Losses were -$87.93 million, 56.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CBIO stock is "Buy." The 12-month stock price forecast is $16.32, which is an increase of 5,527.59% from the latest price.
News
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIO
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...
SHAREHOLDER ALERT: Weiss Law Investigates Catalyst Biosciences, Inc.
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. ("Catalyst" o...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - December 29, 2022) - Rigrodsky Law, P.A. is investigating Catalyst Biosciences, Inc. ("Catalyst") (NASDAQ CM: CBIO) regarding possible breaches of fiduciary dut...
CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Catalyst Biosciences, Inc. (NASDAQ: CBIO) and GNI Group Ltd. is fair to Catalyst shar...
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Acquires F351, a Phase 3 Drug to Treat Fibrosis
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special,...
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a ...
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
Company to Announce a Record Date for Initial Distribution in Due Course Company to Announce a Record Date for Initial Distribution in Due Course
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quar...
JDS1, LLC Terminates Proxy Contest at Catalyst's 2022 Annual Meeting
FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stoc...
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
Encourages Stockholders to Vote on the WHITE Proxy Card Encourages Stockholders to Vote on the WHITE Proxy Card
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company's Nominees on the WHITE Proxy Card
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company's Nom...
Catalyst Biosciences Publishes New Investor Presentation
Provides Details on Current Board's Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution
Catalyst Biosciences Announces Support from Largest Single Stockholder
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst's Nominees at the Company's 2022 Annual Meeting
JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders
FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Bioscien...
Catalyst Biosciences Sends Letter to Stockholders
Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
Court Denies JDS1's Motion for Expedited Proceedings
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Why Catalyst Biosciences Shares Are Skyrocketing Today
Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale...
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sal...
Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Ph...
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022.
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended Dece...